Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2020-07-13 Capital/Financing Update
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a letter from Larimar Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It references the Securities Act of 1933 and Rule 461, which relate to securities registration and offering processes. The document is short (1385 characters) and is a formal request related to a registration statement becoming effective, not a financial report or detailed filing. This type of document is an announcement or procedural correspondence related to capital raising activities, specifically the acceleration of a registration statement's effectiveness. Therefore, it fits best under Capital/Financing Update (CAP).
2020-07-13 English
Regulatory Filings 2020
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, when a document does not fit any specific category or lacks sufficient information, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of readable content.
2020-07-10 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-01 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-30 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-30 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.